Quadrant Capital Group LLC Increases Stock Holdings in Medtronic PLC $MDT

Quadrant Capital Group LLC increased its stake in Medtronic PLC (NYSE:MDT) by 27.4% in the second quarter, Holdings Channel reports. The institutional investor owned 15,185 shares of the medical technology company’s stock after acquiring an additional 3,267 shares during the period. Quadrant Capital Group LLC’s holdings in Medtronic were worth $1,324,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. AXQ Capital LP lifted its position in Medtronic by 25.6% during the 2nd quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock worth $862,000 after acquiring an additional 2,013 shares during the period. Legacy Advisory Services LLC purchased a new position in shares of Medtronic in the first quarter worth about $541,000. GC Wealth Management RIA LLC lifted its holdings in shares of Medtronic by 20.6% during the second quarter. GC Wealth Management RIA LLC now owns 33,569 shares of the medical technology company’s stock worth $2,926,000 after purchasing an additional 5,734 shares during the period. Verdence Capital Advisors LLC increased its holdings in Medtronic by 22.0% in the 2nd quarter. Verdence Capital Advisors LLC now owns 29,396 shares of the medical technology company’s stock worth $2,562,000 after buying an additional 5,296 shares during the period. Finally, World Investment Advisors increased its holdings in Medtronic by 1.9% in the 2nd quarter. World Investment Advisors now owns 156,107 shares of the medical technology company’s stock worth $13,608,000 after buying an additional 2,868 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic Stock Down 0.5%

MDT stock opened at $104.53 on Friday. Medtronic PLC has a one year low of $79.29 and a one year high of $106.33. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01. The firm’s fifty day moving average is $96.06 and its 200 day moving average is $91.66. The firm has a market cap of $134.00 billion, a PE ratio of 28.79, a P/E/G ratio of 2.42 and a beta of 0.77.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The business had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same period in the prior year, the company posted $1.26 EPS. The company’s revenue for the quarter was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Analysts Set New Price Targets

Several analysts have commented on MDT shares. Needham & Company LLC restated a “hold” rating on shares of Medtronic in a research note on Thursday, August 14th. Barclays raised their target price on shares of Medtronic from $109.00 to $111.00 and gave the stock an “overweight” rating in a report on Thursday, November 20th. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a report on Friday, November 14th. Cowen reaffirmed a “buy” rating on shares of Medtronic in a research report on Friday, November 14th. Finally, Citigroup boosted their price objective on Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a report on Tuesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $110.44.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares in the company, valued at approximately $3,261,621.70. This represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.